Pilot Study of Interferon-α with and without Amantadine for the Treatment of Hepatitis C in HIV Co-infected Individuals on Antiretroviral Therapy

Sax, Hugo; Friedl, Andrée; Renner, Eberhard L.; Steuerwald, Michael; Weber, Rainer

doi:10.1007/s15010-001-2045-2

Cited by 8 publications

(6 citation statements)

References 23 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among 107 references identified, 76 studies were excluded for the following reasons: 23 studies were nonrandomized [16,; 12 studies did not mention ETR or SR [45][46][47][48][49][50][51][52][53][54][55][56]; 20 studies did not compare treatment with and without amantadine but other combinations of treatments including amantadine [18,[57][58][59][60][61][62][63][64][65][66][67][68][69][70][71][72][73][74][75]; 2 studies concerned HIV-HCV co-infected patients [76,77]; 2 studies were performed in transplanted patients [78,79]; 1 study did not specify whether patients had received previous therapy or not [80]; 2 did not specify the exact number of patients randomized [81,82]; 14 preliminary studies were excluded as the latest publication of the trial was available [83][84][85][86][87]…”

Section: Resultsmentioning

confidence: 99%

Evaluation of amantadine in chronic hepatitis C: a meta-analysis

Deltenre

Henrion

Canva

et al. 2004

Journal of Hepatology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Evaluation of amantadine in chronic hepatitis C: a meta-analysis

Deltenre

Henrion

Canva

et al. 2004

Journal of Hepatology

View full text Add to dashboard Cite

“…Thirteen clinical trials have studied the use of amantadine as first‐line treatment for CHC infection. Eighty‐nine patients in five observational trials were treated with amantadine 200 mg daily alone for 3–12 months; although a biochemical response was seen in some patients, none achieved a SVR [16–20]. Six randomized trials were performed to evaluate interferon‐alpha and amantadine combination therapy as first‐line therapy.…”

Section: Resultsmentioning

confidence: 99%

“…performed a pilot study in which nine patients with HIV co‐infection on antiretroviral therapy were treated with interferon‐alpha with or without amantadine. Neither treatment regimen resulted in SVR, suggesting that the addition of amantadine to interferon has little effect in this patient population [19].…”

Section: Resultsmentioning

confidence: 99%

Amantadine in treatment of chronic hepatitis C virus infection?

Lim

Wooten

Siegel

et al. 2005

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Treatment of chronic hepatitis C (CHC) continues to be an important and growing challenge. As the response rate to FDA-approved treatment improved over the past decade, we are facing increasing number of difficult-to-treat patients such as those who have failed prior anti-viral therapy. The role of amantadine in the treatment of CHC remains unclear. Studies thus far have produced conflicting results, and type II error could not be excluded. This review summarized results published in the literature from 1997 to 2003, and reviewed the existing questions and controversies regarding the use of amantadine. Current literature suggests that amantadine is ineffective as monotherapy. Amantadine increased the sustained virologic response of certain treatment naïve patients when used in combination with interferon, and may be effective as an adjunct to interferon-based combination therapy in some patients who have failed or relapsed on prior therapy. Factors such as small sample size, patient characteristics, and differences in treatment protocols including amantadine preparation and duration of therapy might explain the conflicting observations of various studies. Further investigations are needed to define optimal dosing and formulation of amantadine, and its appropriate role in management of CHC infection.

show abstract

“…A pilot study conducted with IFN-␣ plus amantadine was disappointing because of inactivity and tolerability [117].…”

Section: Hepatitis C Therapymentioning

confidence: 99%

HIV and Hepatitis C Virus: Facts and Controversies

et al. 2003

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection occurs in about one-third of HIV-seropositive patients and in about 90% of HIVpositive drug abusers. After the introduction of highly active antiretroviral therapy (HAART) and the subsequent reduction in mortality from opportunistic infections, HCV-related liver failure has become a frequent cause of death in HIV-positive patients. In HIV-seropositive patients, the course of HCV infection is accelerated and there is evidence that HCV is an important factor for HIV progression. Consequently, it is important to establish the appropriate treatment for HCV infection in HIV-seropositive patients. This review examines the epidemiology, physiopathology, diagnostics and treatment of HIV/HCV coinfection with particular regard to the impact of HAART.

show abstract

Pilot Study of Interferon-α with and without Amantadine for the Treatment of Hepatitis C in HIV Co-infected Individuals on Antiretroviral Therapy

Abstract: Among patients on highly active antiretroviral therapy, the addition of interferon-alpha with or without amantadine was inefficient and poorly tolerated, but had no negative influence on HIV infection. Eligibility for the study was unexpectedly low.

Cited by 8 publications

References 23 publications

Evaluation of amantadine in chronic hepatitis C: a meta-analysis

Evaluation of amantadine in chronic hepatitis C: a meta-analysis

Amantadine in treatment of chronic hepatitis C virus infection?

HIV and Hepatitis C Virus: Facts and Controversies

Contact Info

Product

Resources

About